Abstract Sodium hydrosulfide (NaHS) has presented antihypertensive and antioxidant effects and may reduce circulating soluble fms-like tyrosine kinase-1 (sFlt-1). We examined whether NaHS prevents maternal and fetal detrimental changes in a model of hypertension in pregnancy induced by N(G)-nitro-L-arginine methyl ester (L-NAME). Forty pregnant rats were divided into four groups (n = 10 per group): Norm-Preg, Preg + NaHS, HTN-Preg, or HTN-Preg + NaHS. Systolic blood pressure (SBP), number of viable fetuses, litter size, pups, and placentae weights were recorded. Circulating plasma sFlt-1, vascular endothelial growth factor (VEGF), myeloperoxidase (MPO), trolox equivalent antioxidant capacity (TEAC) levels, and biochemical determinants of nitric oxide (NO) formation were assessed. SBP values were elevated in the HTN-Preg group on gestational days 16, 18, and 20. However, HTN-Preg + NaHS group presented lower SBP values on days 18 and 20. Lower number of viable fetuses and litter size were found only in HTN-Preg group compared to other. Reductions in placental weight were found in HTNPreg and HTN-Preg + NaHS groups. Increases in fetal weight were found only in Preg + NaHS group. Increases in circulating sFlt-1 and VEGF levels were observed only in HTN-Preg group compared to other. Higher MPO and lower TEAC plasma levels were found in HTN-Preg + NaHS and HTN-Preg groups. NO was diminished in HTN-Preg animals, and NaHS treatment increased NO levels only in hypertensive pregnant animals. Treatment with NaHS prevents hypertension in pregnancy and concomitantly reduces circulating plasma sFlt-1 and VEGF levels; this correlates with improved litter size with more viable fetuses and increase in NO levels. However, these beneficial effects presented no relation with oxidative stress.
Introduction
Preeclampsia affects ∼5-8 % of pregnancies in the USA and eight million worldwide (Uzan et al. 2011) . Currently, preeclampsia is a major cause of fetal morbidity and mortality and causes 15-20 % of maternal deaths (Chang et al. 2003) . Importantly, there is no Bcure^for preeclampsia except for preterm delivery of the baby and placenta, leaving a major health risk for both babies and mothers (Uzan et al. 2011; Palei et al. 2013) . Preeclampsia is manifested as maternal hypertension after 20 weeks of gestation (Noris et al. 2005) , and the mechanisms involved are not clearly understood. In this concern, elevated levels of circulating soluble fms-like tyrosine kinase-1 (sFlt-1), the soluble form of the vascular endothelial growth factor (VEGF) receptor, has been considered a key factor to the hypertension and multisystem organ injury during preeclampsia (Levine et al. 2004; Di Marco et al. 2009 ).
It has been reported that dysregulation of hydrogen sulfide (H 2 S) producing enzymes contributes to maternal hypertension and impaired placental vascularization in preeclampsia. Moreover, inhibition of H 2 S production in mice leads to hypertension, abnormal vascularization of the placenta, and reduced fetal weight . Recently, Holwerda et al. (2014) reported that H 2 S donor (sodium hydrosulfide (NaHS)) may reduce circulating sFlt-1, which, in turn, may decrease maternal blood pressure and may play an important role in the pathogenesis of hypertension in pregnancy. In addition, H 2 S donors have presented proangiogenic (Papapetropoulos et al. 2009; Wang et al. 2010) , antioxidative stress (Kabil et al. 2014) , antiinflammatory (Sodha et al. 2009) , and antihypertensive effects (Ahmad et al. 2012) ; thus, targeting H 2 S may help to clarify the physiopathology of preeclampsia.
Several lines of evidence support the concept that there may be reduction of endogenous nitric oxide (NO) production during hypertension in pregnancy (Eleuterio et al. 2013; Pimentel et al. 2013; Possomato-Vieira and Khalil 2016; Wang et al. 2015) and that chronic NO synthase blockade from mid to late gestation in rats results in many pathological changes similar to those found in women with preeclampsia (Agunanne et al. 2010; Ramesar et al. 2011; Gillis et al. 2015; Morris et al. 2016) . Thus, in this study, pregnant rats were treated chronically with N(G)-nitro-L-arginine methyl ester (L-NAME) from mid to late gestation in order to block NO synthesis. Therefore, we hypothesized that NaHS attenuates the deleterious (maternal and fetal) changes in a rat model of hypertension in pregnancy and these beneficial effects are associated to the reductions in circulating sFlt-1. In order to investigate mechanisms involved in this phenomenon, we measured circulating sFlt-1 and VEGF and biochemical determinants of oxidative stress and NO formation.
Materials and methods

Animals and experimental protocol
Wistar rats (200-250 g) were housed in cages at 22 ± 2°C on a 12-h light/dark cycle and given free access to water and rat chow. Each female rat was separately mated overnight. Day 0 of pregnancy was defined as the day when spermatozoa were found in a vaginal smear.
On day 14 of pregnancy, each pregnant rat mother was first placed into a single cage and randomized to one of the four treatment groups *(n = 10 per group, total of 40 rats): Norm-Preg, Preg + NaHS, HTN-Preg, and HTN-Preg + NaHS. Pregnant rats received daily intraperitoneal (i.p.) injections of 0.9 % saline solution in Norm-Preg group or i.p. injections of NaHS (Sigma, St. Louis, MO, no. 161527) 50 µmol/kg/twice daily for 7 days (Holwerda et al. 2014) in Preg + NaHS group, or i.p. injections of L-NAME (Sigma, St. Louis, MO, no. 5751; 60 mg/kg/daily) (Yang et al. 2011) in HTN-Preg group, or i.p. injections of L-NAME (60 mg/kg/daily) (Yang et al. 2011 ) and i.p. injections of NaHS (50 μM/kg/twice daily for 7 days) (Holwerda et al. 2014) in HTN-Preg + NaHS group. This NaHS treatment (50 μmol/kg = 0.30 mg/kg) was chosen based on previous study (Holwerda et al. 2014) . So, the rats received the first NaHS injection 3 h before and 1 h after the systolic blood pressure measurements. Rats were euthanized on gestation day 21 under overdose of isoflurane followed by exsanguination. Blood samples were collected in lyophilized ethylenediaminetetraacetic acid (EDTA) (Vacuntainer BectonDickinson, Oxford, UK) for plasma separation. Plasma was stored at −80°C until use for biochemical analysis.
All procedures for animal experimentation were approved by the Ethics Committee, Biosciences Institute of Botucatu, State University of Sao Paulo (protocol no. 619/2014).
Blood pressure measurements
Systolic blood pressure (mmHg) was measured on gestational days 14, 16, 18, and 20, Ribeirao Preto, Sao Paulo, Brazil, catalog no. EFF 306) . Briefly, all pregnant rats were first acclimated in a quiet room, conditioned, and restrained for 5-10 min in a warm box (Insight, Ribeirao Preto, Sao Paulo, Brazil, catalog no. EFF-307) to the measurements for 3 days before the pregnancy day 14 (these data were discarded), and then, the baseline systolic blood pressure was determined as the average of the cuff inflation-deflation (three to six) cycles by a trained operator on pregnancy day 14 (Gonçalves-Rizzi et al. 2016 ).
Effects on placenta and fetuses
On gestational day 21, after euthanasia, animals were placed in supine position and cesarean section was performed. The number of viable fetuses, litter size, fetal weight, and placental weight were recorded. Viable fetuses were determined as those which showed no macroscopical sign of malformation and could apparently have a normal outcome with the progression of the pregnancy, as previously reported (Ma et al. 2010 ).
Determination of sFlt-1 and VEGF
Commercial enzyme immunoassay (ELISA) kits for sFlt-1 (no. MVR100) and VEGF (no. RRV00) both of R&D Systems Inc. (Minneapolis, MN) were used to determine plasma levels. Assays were performed according to the manufacturer's instructions. Plasmatic levels of sFlt-1 and VEGF were expressed in pg/mL.
Determination of myeloperoxidase activity
Circulating plasma levels of myeloperoxidase (MPO) reflect the inflammatory response, as according to the method previously proposed by Suzuki et al. (1983) . Briefly, 30 μL of centrifuged plasma samples received 100 μL of tetramethyl benzidine (TMB) and 0.04 % H 2 O 2 . Posteriorly, microplate was incubated for 10 min at 37°C, protected from light. The reaction was stopped with 100 μL H 2 SO 4 (2 N), and the absorbance at 450 nm with correction to 630 nm was read with the spectrophotometer (Synergy 4, BIOTEK, Winooski, VT). The results were expressed in ΔA 630 /min/mL).
Measurements of plasma antioxidant capacity
The trolox equivalent antioxidant capacity (TEAC) was performed as previously described by Erel (2004) . Briefly, a standard curve was established using 100 μg of Trolox (6-hidroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, Sigma, St. Louis, MO, no. 238813) in 1 mL of sodium acetate buffer (0.4 M, C 2 H 3 NaO 2 ·3H 2 O) + glacial acetic acid (0.4 M). Firstly, 20 μL of plasma samples were added to 200 μL of sodium acetate buffer + glacial acetic acid, and the absorbance at 660 nm was read with the spectrophotometer (Synergy 4, BIOTEK, Winooski, VT). Secondly, 20 μL of sodium acetate buffer (0.03 M) and glacial acetic acid (0.03 M) + H 2 O 2 + 2,2-azino-bis(3-ethylbenz-thiazolin-6 sulfonic acid (ABTS, Sigma A 1888) was added to the samples and incubated for 5 min. Finally, a second reading was performed at 660 nm. The second reading values were subtracted from the first reading values, and the antioxidant activity was expressed as mmol of Trolox equivalent/L.
Measurement of plasma nitrite + nitrate concentrations
The plasma nitrite + nitrate (NOx) concentrations were determined in duplicate using the Griess reaction, as previously described (Dias-Junior et al. 2010) . Briefly, 40 mL of plasma was incubated with the same volume of nitrate reductase buffer (0.1 M potassium phosphate, pH 7.5, containing 1 mM β-nicotinamide adenine dinucleotide phosphate and 2 U of nitrate reductase/mL) in individual wells of a 96-well plate. Samples were allowed to incubate overnight at 37°C in the dark; 8 mL of freshly prepared Griess reagent (1 % sulfanilamide, 0.1 % naphthylethylenediamine dihydrochloride in 5 % phosphoric acid) was added to each well, and the plate was incubated, for 15 additional minutes, at room temperature. A standard nitrate curve was obtained by incubating sodium nitrate (0.2-200 μM) with the same reductase buffer. The NOx levels in plasma were expressed in μmol/L.
Statistical analysis
Using commercially available statistical software (GraphPad Prism® 6.0 for Windows, San Diego, CA), a Shapiro-Wilk test was applied to verify normality of data distribution. Systolic blood pressure measurements were submitted to a two-way analysis of variance (ANOVA) with time and treatment defined as main effects, followed by Tukey's test for multiple comparisons among groups or by a Dunnett's test to compare measurements on pregnancy days 16, 18, and 20. Paired t tests were used to compare fetal and placental changes or sFlt-1, VEGF, TEAC, MPO, and NO levels.
Statistical significance was considered at P < 0.05. All values are expressed as mean ± SEM.
Results
There were no significant differences in the systolic blood pressure values (118 to 127 ± 4 mmHg) among the four groups on day 14 (P > 0.05, Fig. 1 ). Systolic blood pressure values were elevated in the HTN-Preg group on days 16, 18, and 20 (145 ± 5, 149 ± 3, and 140 ± 4 mmHg, respectively, P < 0.05, Fig. 1 ). However, HTN-Preg + NaHS group presented a trend of low values on day 16 (132 ± 5 mmHg), and lower systolic blood pressure values were significantly observed on days 18 and 20 (129 ± 4 and 126 ± 3 mmHg) compared with HTN-Preg group (P < 0.05, Fig. 1 ).
Lower number of viable fetuses was found only in HTNPreg group (7 ± 0.7, P < 0.05, Fig. 2 ) compared with NormPreg, Preg + NaHS, and HTN-Preg + NaHS groups (11 ± 1.0, 12 ± 0.7, and 11 ± 1.0, respectively, Fig. 2) . Also, the number of pups (litter size) was significantly lower in HTN-Preg group (9.2 ± 0.7) compared with Norm-Preg, Preg + NaHS, or HTN-Preg + NaHS groups (13 ± 1, 13 ± 1, or 12 ± 1, respectively). Surprisingly, the fetal weight was significantly higher only in Preg + NaHS group (3.5 ± 0.11 g, P < 0.05, Fig. 2 ) compared with Norm-Preg, HTN-Preg, and HTN-Preg + NaHS groups (2.9 ± 0.1, 3.1 ± 0.03, and 3.2 ± 0.06 g, respectively, Fig. 2 ). Lower placental weights were found in both groups which received L-NAME without (HTN-Preg group, 0.53 ± 0.01 g, P < 0.05, Fig. 2 ) or with NaHS (HTNPreg + NaHS group, 0.55 ± 0.01 g, P < 0.05, Fig. 2 ). Both Norm-Preg and Preg + NaHS presented higher placental weight (0.63 ± 0.01 and 0.63 ± 0.01 g, respectively, P < 0.05) compared with HTN-Preg and HTN-Preg + NaHS groups (Fig. 2) .
NaHS blunted increases in circulating plasma sFlt-1 and VEGF levels induced by L-NAME (both P < 0.05, Fig. 3 ). Increased circulating sFlt-1 plasma levels were observed only in HTN-Preg group compared with Norm-Preg, Preg + NaHS, and HTN-Preg + NaHS (368.2 ± 54.17, 162.2 ± 4.37, 138.8 ± 6.57, and 174.3 ± 14.37 pg/mL, respectively, P < 0.05, Fig. 3 ). Higher circulating plasma VEGF levels were found only in HTN-Preg group compared with Norm-Preg, Preg + NaHS, and HTN-Preg + NaHS (77.69 ± 4.61, 58.41 ± 6.14, 61.45 ± 3.62, and 60.74 ± 2.48 pg/mL, respectively, P < 0.05, Fig. 3 ).
Both HTN-Preg and HTN-Preg + NaHS presented decreases in antioxidant capacity (0.042 ± 0.016 and 0.039 ± 0.017, respectively) compared with Norm-Preg and Preg + NaHS groups (0.11 ± 0.013 and 0.12 ± 0.011, respectively, P < 0.05, Fig. 4) . Also, HTN-Preg and HTN-Preg + NaHS presented increases in myeloperoxidase levels (2.06 ± 0.10 and 2.32 ± 0.12, respectively) compared with Norm-Preg and Preg + NaHS groups (1.12 ± 0.20 and 1.35 ± 0.15, respectively, P < 0.05, Fig. 4) .
We evaluated NO bioavailability by measuring plasma nitrite and nitrate concentrations. We found a diminished NO bioavailability in HTN-Preg group (45.45 ± 5.76 μmol/L, P < 0 . 0 5 ) c o m p a r e d t o N o r m -P r e g g r o u p (73.34 ± 6.61 μmol/L). Treatment with NaHS did not alter NOx production in normotensive pregnant rats (Preg + NaHS group, 63.50 ± 15.33 μmol/L) versus Norm-Preg group. However, NaHS promotes an increase in NOx production in hypertensive animals (HTN-Preg + NaHS group, 134.10 ± 14.52 μmol/L, P < 0.05, Fig. 4 ).
Discussion
This study shows that treatment with NaHS prevents hypertension in pregnancy and concomitantly reduces circulating plasma sFlt-1 and VEGF levels, with a correlation in improvement of the litter size with more viable fetuses. However, these beneficial effects presented no relation with oxidative stress. Also, reductions in placental weights induced by L-NAME were not affected by NaHS.
In our hands, following treatment with L-NAME, we observed reductions in placenta weights without changes in fetal weights in hypertensive pregnant groups without (HTN-Preg) or with NaHS (HTN-Preg + NaHS). However, in normal pregnant rats treated with NaHS, we observed an increase in fetal weight without changes in placental weight (Preg + NaHS group). This may be due to the fact that the more rapid growth of the fetus during later gestation places significant demands on placental transport function. The relative lag in placental weight versus fetal weight suggests that there may be a compensatory mechanism such as enhanced placental transport capacity to meet the demands of the growing fetus. In fact, the lack of changes in placental weight may result from placental maturational processes during late gestation rather than increased placental size, and this phenomenon has been shown in other studies (Mayr et al. 2005; Ma et al. 2010; Kaya et al. 2011; Ramesar et al. 2011; Yang et al. 2011; Baijnath et al. 2014; Motta et al. 2015; Shi et al. 2015) .
Importantly, this study demonstrates that NaHS prevents hypertension in pregnancy and concomitantly reduces circulating plasma sFlt-1 and VEGF levels, which correlates with improved litter size with more viable fetuses. Supporting our results, a previous study suggested that NaHS may be involved in reducing sFlt-1, which, in turn, may decrease maternal blood pressure during hypertension in pregnancy induced by overexpression of sFlt-1, and that Bin vitro^NaHS was proangiogenic in an endothelial tube assay and attenuated the antiangiogenic effects of sFlt-1 (Holwerda et al. 2014) . Those authors proposed that the reductions in circulating sFlt-1 were due to upregulation of VEGF induced by NaHS (Holwerda et al. 2014) . We observed an increase in plasmatic VEGF in hypertensive animals that was blunted following treatment with NaHS. The diminished bioavailability of NO caused by L-NAME may induce a consistent vasoconstricted state in our hypertensive pregnant animals, and considering that VEGF normally acts as a vasodilator, its increase may represent an unsuccessful vascular rescue response. H 2 S donor may promote improvement of blood flow by a non-NOmediated relaxation (Tang et al. 2013; Dunn et al. 2016) , and this relaxation may counterbalance the vasoconstrictive state in hypertensive animals treated with NaHS, consequently normalizing the VEGF levels. This is supported by previous results showing that maternal plasma VEGF concentrations increased before the clinical onset of preeclampsia and were further elevated during the vasoconstricted state observed in preeclampsia (Bosio et al. 2001) . We suggest that NaHS could affect circulating sFlt-1 and VEGF levels, since NaHS prevented both elevations of circulating sFlt-1 and VEGF, which were associated with antihypertensive effects and prevention of detrimental fetal changes.
Also, supporting our results showing increases in circulating sFlt-1 (Ramesar et al. 2011) and VEGF induced by L-NAME, recent evidences have emphasized that VEGF overexpression may increase sFlt-1 levels, resulting in pregnancy losses, placental vascular defects, increases in the number of , and 20 of gestation among the four groups: normal pregnancy (Norm-Preg), pregnancy + NaHS (Preg + NaHS), pregnant rats treated with L-NAME (HTN-Preg), and pregnant rats treated with L-NAME and NaHS (HTN-Preg + NaHS). Values represent mean ± SEM. *P < 0.05, HTN-Preg versus Norm-Preg and Preg + NaHS. # P < 0.05 HTN-Preg + NaHS vs. HTN-Preg resorption sites with decreases in the number of viable fetuses, and preeclampsia-like symptoms including hypertension in the mother (Fan et al. 2014) . Moreover, sFlt-1 knockdown in VEGF-overexpressing animals aggravated the symptoms produced by VEGF overexpression alone (Fan et al. 2014) . Therefore, these previous findings suggested that although sFlt-1 is an endogenous antagonist of VEGF, resulting in deleterious effects to the mother during preeclampsia (Thadhani et al. 2011 ), sFlt-1 may play an essential role in maintaining vascular integrity in the placenta by sequestering excess of maternal VEGF (Ozawa et al. 2004) , potentially contributing to the pathogenesis of preeclampsia (Zhao et al. 2009 ). Thus, the present study suggests that there is an important regulatory relationship between increases in circulating sFlt-1 and VEGF levels, i.e., indicating that VEGF is tightly controlled at the maternal-fetal interface, at least in part through modulation by sFlt-1 (Miquerol et al. 2000) .
The VEGF acts through VEGF receptor 2 and can directly stimulate the production of sFlt-1 by modulating the alternative splicing of Flt-1's transcripts (Saito et al. 2013 ), driving sFlt-1 production in different cell types, including human placenta (Ahmad and Ahmed 2004) . Therefore, the reductions in circulating plasma sFlt-1 and VEGF levels observed with NaHS may have prevented the concomitant damages to the mother and fetus that would otherwise be caused by VEGF signaling (Miquerol et al. 2000; Fan et al. 2014) . So, these results provide potentially clinical implications for the design of therapies for preeclampsia that manipulate sFlt-1 and/or VEGF levels, being through systemic administration of VEGF or extracorporeal removal of circulating sFlt-1 (Thadhani et al. 2011 ). Thus, it should be weighted that minor deviations from normal VEGF and sFlt-1 levels for therapeutic purposes during preeclampsia may have serious consequences to mother and fetus (Zhao et al. 2009; Saito et al. 2013) .
Previous findings have showed significant raised plasma sFlt-1 and VEGF levels in preeclampsia compared to normotensive healthy pregnancies (Zhao et al. 2009; Saito et al. 2013; Fan et al. 2014) , and currently, there is a potential for Fig. 3 Circulating free sFlt-1 and VEGF plasma levels. Normal pregnancy (Norm-Preg), pregnancy + NaHS (Preg + NaHS), pregnant rats treated with L-NAME (HTN-Preg), and pregnant rats treated with L-NAME and NaHS (HTN-Preg + NaHS). Values represent mean ± SEM. *P < 0.05 versus Norm-Preg 
* *
Norm-Preg Preg + NaHS HTN-Preg HTN-Preg + NaHS Placental weight (g) Fig. 2 Fetal and placental parameters. Normal pregnancy (Norm-Preg), pregnancy + NaHS (Preg + NaHS), pregnant rats treated with L-NAME (HTN-Preg), and pregnant rats treated with L-NAME and NaHS (HTNPreg + NaHS). Values represent mean ± SEM. *P < 0.05 versus NormPreg treating symptoms in the mother through manipulation of plasma sFlt-1 levels (Thadhani et al. 2011) . We then explored more mechanisms relating the source of increases in circulating sFlt-1. In this regard, sFlt-1 may be originated from circulating mononuclear cells (Rajakumar et al. 2005) , releasing simultaneously proteases and reactive oxygen species that along with sFlt-1 cause vascular endothelial injury (Wallace et al. 2014) . Accordingly, we found that MPO, a prooxidant enzyme abundantly expressed in neutrophil granulocytes, presented high levels in groups that received L-NAME (HTNPreg and HTN-Preg + NaHS groups). Furthermore, exogenous H 2 S donors have showed to protect against ischemia/ reperfusion injury, exhibiting antiinflammatory effects (Bos et al. 2009; Sodha et al. 2009) . Also, endogenous H 2 S reduced oxidative stress after renal ischemia/reperfusion (Bos et al. 2013) . However, our results display that NaHS failed in affecting changes in MPO and antioxidant capacity caused by L-NAME; thus, we propose that beneficial effects with NaHS observed here are not associated with modulations of antioxidant response and oxidative stress. Therefore, the theory that sFlt-1 originates from circulating mononuclear cells causing vascular endothelial injury is not confirmed by the present study, since NaHS reduced circulating plasma sFlt-1 levels and concomitantly presented antihypertensive effects with no change in MPO levels (Rajakumar et al. 2005) .
In order to expand our findings, we measured NO in our animals. In our hands, treatment with NaHS increased NO levels in hypertensive pregnant rats (HTN-Preg + NaHS group) but not in normotensive pregnant rats (Preg + NaHS). Studies on the cross talk between H 2 S and NO have shown conflicting results. It has been found that H 2 S inhibited eNOS activity and thus the synthesis of NO in endothelium (Kubo et al. 2007) . Also, H 2 S suppressed NO production by inhibition of eNOS transcription, abundance, and activity in aortic tissue (Geng et al. 2007 ). On the other hand, treatment with NaHS promoted an increase in NO production in endothelial cells (Predmore et al. 2011; Altaany et al. 2013) , and knockdown of cystathionine γ-lyase (CSE), the producing enzyme of H 2 S, diminished NO production, while overexpression of CSE increased NO production in endothelial cells (Altaany et al. 2013) . Moreover, H 2 S increased eNOS phosphorylation (Predmore et al. 2011; Altaany et al. 2013) . Studies suggest an important role of NO in maintaining healthy pregnancy (Nelson et al. 2000; Shaamash et al. 2000; Dötsch et al. 2001) ; thus, the increases in NO may be partially responsible for improvements followed by treatment with NaHS. The inhibition of NOS promoted by L-NAME suggests that the increased levels of NO observed in animals from HTN-Preg + NaHS group may occur in a NOSindependently pathway. For instance, we strongly recommend that future researches focus on the cross talk between H 2 S and NO in healthy and hypertensive pregnancies, as this is a unique physiological condition that may trigger different responses compared to a non-pregnant situation.
Importantly, some limitations should be taken into account. Firstly, as a unique condition in rats, there is a second circulatory system via the amniotic vessels in addition to blood supply from the uterine artery; thus, L-NAME-induced changes on microcirculatory and/or cellular levels could have influenced placenta weight, litter size, and viable fetuses. Since parameters of cellular function were not evaluated in this study, more investigations are needed to clarify functions of the utero-placental unit in preeclampsia-like syndrome. Furthermore, we failed to detect any significant differences in fetal weights with L-NAME, since intrauterine growth retardation may be a feature of preeclampsia. Secondly, as clinical studies in obstetric patients always remain a delicate ethical issue, animal models serve to answer specific questions regarding the pathophysiology of preeclampsia. Moreover, comparability of data from clinical studies and experimental models always remains speculative (Podjarny et al. 2004; McCarthy et al. 2011) . Thirdly, proteinuria was not assessed Plasma antioxidant capacity, MPO activity, and nitrite + nitrate levels. Normal pregnancy (Norm-Preg), pregnancy + NaHS (Preg + NaHS), pregnant rats treated with L-NAME (HTN-Preg), and pregnant rats treated with L-NAME and NaHS (HTN-Preg + NaHS). Values represent mean ± SEM. *P < 0.05 versus Norm-Preg; # P < 0.05 versus HTN-Preg in this study. Although protein excretion has been figured for years as an essential parameter for the diagnosis of preeclampsia, it is no longer mandatory for diagnostic purposes. Importantly, proteinuric and non-proteinuric preeclampsias are now considered in two separate categories (Mol et al. 2016 ). In addition, experimental studies using L-NAME have shown conflicting results, either elevated (Souza et al. 2012) or unchanged proteinuria (Ramesar et al. 2010) in pregnant rats. In fact, it has been reported that there is a gradual increase in proteinuria throughout pregnancy in rats as a result of selective glomerular filtration and non-selective reabsorption in the proximal tubule, i.e., urinary protein concentrations in pregnant rats are not reliable to detect significant differences (Alexander et al. 1999) . Lastly, further studies are necessary to address the potential therapeutic of H 2 S donor analogs during preeclampsia .
Treatment with NaHS prevents hypertension in pregnancy induced by L-NAME and concomitantly reduces circulating plasma sFlt-1 and VEGF levels; this correlates with improving in the litter size with more viable fetuses, suggesting that although high circulating sFlt-1 may cause damage to the mother, the excess of maternal VEGF can be deleterious to the fetuses. Also, NaHS treatment induces increases in NO that may be partially responsible for the effects of NaHS on hypertensive pregnancy. However, these beneficial effects with NaHS presented no relation with oxidative stress.
